Matthew D Hickey1, Charles R Salmen, Dan Omollo, Brian Mattah, Kathryn J Fiorella, Elvin H Geng, Peter Bacchetti, Cinthia Blat, Gor B Ouma, Daniel Zoughbie, Robert A Tessler, Marcus R Salmen, Harold Campbell, Monica Gandhi, Starley Shade, Betty Njoroge, Elizabeth A Bukusi, Craig R Cohen. 1. *Division of Internal Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco (UCSF), San Fransisco, CA; †Mfangano Island Research Group, Organic Health Response, Homa Bay, Kenya; ‡Microclinic International (MCI), San Francisco, CA; §Department of Family and Community Medicine, University of Minnesota, Minneapolis, MN; ‖Department of Environmental Science, Policy and Management, University of California, Berkeley, Berkeley, CA; ¶Department of Medicine, Division of HIV/AIDS, University of California, San Francisco (UCSF), San Francisco, CA; #Department of Epidemiology and Biostatistics, University of California, San Francisco (UCSF), San Francisco, CA; **Department of Surgery, University of California, San Francisco (UCSF) East Bay, Oakland, CA; ††Center for AIDS Prevention Studies, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA; ‡‡Centre for Microbial Research, Kenya Medical Research Institute, Nairobi, Kenya; and §§Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco (UCSF), San Francisco, CA.
Abstract
BACKGROUND: Despite progress in the global scale-up of antiretroviral therapy, sustained engagement in HIV care remains challenging. Social capital is an important factor for sustained engagement, but interventions designed to harness this powerful social force are uncommon. METHODS: We conducted a quasiexperimental study evaluating the impact of the Microclinic Social Network intervention on engagement in HIV care and medication adherence on Mfangano Island, Kenya. The intervention was introduced into 1 of 4 similar communities served by this clinic; comparisons were made between communities using an intention-to-treat analysis. Microclinics, composed of patient-defined support networks, participated in 10 biweekly discussion sessions covering topics ranging from HIV biology to group support and group HIV status disclosure. Nevirapine concentrations in hair were measured before and after study. RESULTS: One hundred thirteen (74%) intervention community participants joined a microclinic group, 86% of whom participated in group HIV status disclosure. Over 22-month follow-up, intervention community participants experienced one-half the rate of ≥ 90-day clinic absence as those in control communities (adjusted hazard ratio: 0.48; 95% confidence interval: 0.25 to 0.92). Nevirapine hair levels declined in both study arms; in adjusted linear regression analysis, the decline was 6.7 ng/mg less severe in the intervention arm than control arm (95% confidence interval: -2.7 to 16.1). CONCLUSIONS: The microclinic intervention is a promising and feasible community-based strategy to improve long-term engagement in HIV care and possibly medication adherence. Reducing treatment interruptions using a social network approach has important implications for individual patient virologic suppression, morbidity, and mortality and for broader community empowerment and engagement in healthcare.
BACKGROUND: Despite progress in the global scale-up of antiretroviral therapy, sustained engagement in HIV care remains challenging. Social capital is an important factor for sustained engagement, but interventions designed to harness this powerful social force are uncommon. METHODS: We conducted a quasiexperimental study evaluating the impact of the Microclinic Social Network intervention on engagement in HIV care and medication adherence on Mfangano Island, Kenya. The intervention was introduced into 1 of 4 similar communities served by this clinic; comparisons were made between communities using an intention-to-treat analysis. Microclinics, composed of patient-defined support networks, participated in 10 biweekly discussion sessions covering topics ranging from HIV biology to group support and group HIV status disclosure. Nevirapine concentrations in hair were measured before and after study. RESULTS: One hundred thirteen (74%) intervention community participants joined a microclinic group, 86% of whom participated in group HIV status disclosure. Over 22-month follow-up, intervention community participants experienced one-half the rate of ≥ 90-day clinic absence as those in control communities (adjusted hazard ratio: 0.48; 95% confidence interval: 0.25 to 0.92). Nevirapine hair levels declined in both study arms; in adjusted linear regression analysis, the decline was 6.7 ng/mg less severe in the intervention arm than control arm (95% confidence interval: -2.7 to 16.1). CONCLUSIONS: The microclinic intervention is a promising and feasible community-based strategy to improve long-term engagement in HIV care and possibly medication adherence. Reducing treatment interruptions using a social network approach has important implications for individual patient virologic suppression, morbidity, and mortality and for broader community empowerment and engagement in healthcare.
Authors: J A Idoko; O Agbaji; P Agaba; C Akolo; B Inuwa; Zuweira Hassan; L Akintunde; B Badung; M Muazu; M Danang; G Imade; J Louis Sankale; Phyllis Kanki Journal: Int J STD AIDS Date: 2007-11 Impact factor: 1.359
Authors: Edwin Wouters; Wim Van Damme; Francis Van Loon; Dingie van Rensburg; Herman Meulemans Journal: Soc Sci Med Date: 2009-08-18 Impact factor: 4.634
Authors: Melissa H Watt; Suzanne Maman; Jo Anne Earp; Eugenia Eng; Philip W Setel; Carol E Golin; Mark Jacobson Journal: Soc Sci Med Date: 2009-03-28 Impact factor: 4.634
Authors: Alexander C Tsai; David R Bangsberg; Susan M Kegeles; Ingrid T Katz; Jessica E Haberer; Conrad Muzoora; Elias Kumbakumba; Peter W Hunt; Jeffrey N Martin; Sheri D Weiser Journal: Ann Behav Med Date: 2013-12
Authors: Cynthia R Pearson; Mark A Micek; Jane M Simoni; Peter D Hoff; Eduardo Matediana; Diane P Martin; Stephen S Gloyd Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Norma C Ware; Monique A Wyatt; Elvin H Geng; Sylvia F Kaaya; Oche O Agbaji; Winnie R Muyindike; Guerino Chalamilla; Patricia A Agaba Journal: PLoS Med Date: 2013-01-08 Impact factor: 11.069
Authors: Nhi Phung; Karen Kuncze; Hideaki Okochi; Alexander Louie; Leslie Z Benet; Igho Ofokotun; David W Haas; Judith S Currier; Tariro D Chawana; Anandi N Sheth; Peter Bacchetti; Monica Gandhi; Howard Horng Journal: Rapid Commun Mass Spectrom Date: 2018-03-15 Impact factor: 2.419
Authors: Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.071
Authors: Laura M Bogart; Glenn J Wagner; William Musoke; Rose Naigino; Sebastian Linnemayr; Emily Maistrellis; David J Klein; Riana B Jumamil; Barbara Mukasa; Ingrid V Bassett; Thomas P Giordano; Rhoda K Wanyenze Journal: AIDS Behav Date: 2017-02
Authors: Gideon Amanyire; Fred C Semitala; Jennifer Namusobya; Richard Katuramu; Leatitia Kampiire; Jeanna Wallenta; Edwin Charlebois; Carol Camlin; James Kahn; Wei Chang; David Glidden; Moses Kamya; Diane Havlir; Elvin Geng Journal: Lancet HIV Date: 2016-08-27 Impact factor: 12.767
Authors: Pamela Bachanas; Daniel Kidder; Amy Medley; Sherri L Pals; Deborah Carpenter; Andrea Howard; Gretchen Antelman; Nicolas DeLuca; Odylia Muhenje; Muhsin Sheriff; Geoffrey Somi; Frieda Katuta; Peter Cherutich; Janet Moore Journal: AIDS Behav Date: 2016-09
Authors: Matthew D Hickey; Dan Omollo; Charles R Salmen; Brian Mattah; Cinthia Blat; Gor Benard Ouma; Kathryn J Fiorella; Betty Njoroge; Monica Gandhi; Elizabeth A Bukusi; Craig R Cohen; Elvin H Geng Journal: AIDS Care Date: 2016-05-04
Authors: Leslie D Williams; A Korobchuk; E Pavlitina; G K Nikolopoulos; B Skaathun; J Schneider; E-G Kostaki; P Smyrnov; T I Vasylyeva; M Psichogiou; D Paraskevis; E Morgan; A Hadjikou; M J Downing; A Hatzakis; S R Friedman Journal: AIDS Behav Date: 2019-05